



# भारत का राजपत्र The Gazette of India

असाधारण

EXTRAORDINARY

भाग II—खण्ड 3—उप-खण्ड (ii)

PART II—Section 3—Sub-section (ii)

प्राधिकार से प्रकाशित

PUBLISHED BY AUTHORITY

सं. 2672]

नई दिल्ली, बृहस्पतिवार, नवम्बर 10, 2016/कार्तिक 19, 1938

No. 2672]

NEW DELHI, THURSDAY, NOVEMBER 10, 2016/KARTIKA 19, 1938

j l k; u vkj mojd ea=ky;

1/4vk/k fohkx1/2

1/2k"Vh; vk/k eW; fu/kkj.k ikf/kdj.k1/2

vkn'sk

ubz fnYyh] 10 uoEcj] 2016

dk-vk- 34301/41/2&jk"Vh; vk/k eW; fu/kkj.k ikf/kdj.k] Hkkjr ljdkj ds j l k; u vkj mojd ea=ky; }kj tkjh dko vko 13941/41/2 rkjh[k 30 eb] 2013 vkj dk- vk- 7011/41/2 rkjh[k 10 epl] 2016 ds l kFk i fBr vk/k 1/4dher fu; a=k. k1/2 vkn'sk] 2013 ds i j k 4] 10] 11] 14] 16] 17 vkj 18 }kj inRr 'kfDr; ka dk iz; kx djs gq] rFkk Hkkjr ljdkj ds j l k; u vkj mojd ea=ky; }kj"Vh; vk/k eW; fu/kkj.k ikf/kdj.k 1/4 f{klr : i ea , ui hi h, gS] ughs dh l kj.kh ds Lralk 1/51/2 es fofufnZV rRdky i Hkkoh vf/kdre dher vkj mDr l kj.kh ds Lralk 1/31/2 vkj 1/41/2 es dh Oe'k% rRLFKkuh i fof"V; ka es fofufnZV icyrk vkj bdkbZ 1/4; fuV% l fgr ml l kj.kh ds Lralk 1/21/2 es dh rRLFKkuh i fof"V es fofufnZV vuq fpr fofufeR; ka ea l s i R; cd dh] LFkkuh; dj] ; fn dkbZ gS dks NkMoj vf/kdre dher ds #i ea fu; r djrh gA

l kj.kh

d l a	vuq fpr fofufeR dk uke	icyrk	bdkbZ	vf/kdre dher 1/4#-1/2
1	2	3	4	5
1.	i j kfyMkDI he Dykj kbM 1/2&ih, , e% buT'D'ku	i j kfyMkDI he Dykj kbM 1/2&ih, , e% 25 fexk- /fey	1 fey	3.45
2.	bQkohj ut xkyh	bQkohj ut - 200 fexk-	1 xkyh	20.17
3.	bekVhuic dS l y	bekVhuic & 400 fexk-	1 dS l y	236.99
4.	Qkyd , l hm dS l y	Qkyd , l hm & 5 fexk-	1 dS l y	5.23

5.	cutkş y ijkDI kbM dhe	cutkş y ijkDI kbM & 2.5%	1 xke	2.18
6.	DykehQus dş l y	DykehQu 100 fexk-	1 dş l y	51.64
7.	, l hVktkyekbM dş l y	, l hVktkyekbM & 250 fexk-	1 dş l y	4.03
8.	l kycw/keky dş l y	l kycw/keky & 4 fexk-	1 dş l y	0.56
9.	işkf l Vkeky vkşy fyD; bM	işkf l Vkeky 120 fexk- /5 fefy	1 fefy	0.49

ukv %

¼d½ l jdkj }kjk bl iækj fu; r dh xbl vkş vf/kl fpr dh xbl vf/kdre dher ¼ku LFkkuh; dj] tks ykxw gkæ l s vf/kd dher ij vuq fpr fofufeŕ; ka ds ckmM ; k tufjd ; k nksuka : i karjka dks cp jgs vuq fpr fofufeŕ; ka ds l Hkh fofuekŕk mi ; Dr l kj.kh ds Lralk ¼5½ ea of.kŕ vf/kdre dher ¼ku LFkkuh; dj] tks ykxw gkæ l s vf/kd l Hkh , s h fofufeŕ; ka dh dher dk v/kkeq[kh i ujh(k.k djaA

¼k½ l Hkh ekStnk fuekŕkvka dks mi ; Dr dffkr vuq fpr fofufeŕ; ka ds vf/kdre [knjk dher mi ; Dr l kj.kh ds Lralk ¼5½ ea fofufnZV vf/kdre dher LFkkuh; dj l fgr l s de gS rkş tgka dgh Hkh ykxw gkş vksk/k ¼eW; fu; æ.k.½ vknş k] 2013 ds işkxkQ 13¼2½ ds vuq kj ml dks ekStnk vf/kdre [knjk dher dks cuk, j[kuk gkskA

¼x½ vxj fuekŕkvka us mi ; Dr l kj.kh ds Lralk ¼5½ ea of.kŕ vf/kdre dher ij l jdkj dks okLro ea Hkxrku fd; k gS ; k ; g nş gS rks os LFkkuh; djka dks tkM+l dŕs gA

¼k½ vksk/k ¼eW; fu; æ.k.½ vknş k] 2013 ds işkxkQ 11 ea fn, x, i ko/kkuka ds rgr l Ecu/k fuekŕkvka dks mi ; Dr l kj.kh ds Lralk ¼5½ ea fofufnZV vf/kdre dher ds vk/kkj ij vuq fpr fofufeŕ; ka ds i Ska ds fy, vf/kdre dher fu/kkŕj dja fuekŕk vksk/k ¼eW; fu; æ.k.½ vknş k] 2013 ds işkxkQ 24 ds rgr QkæZ V ea vf/kl upuk dh rkjh[k l s vkbŕ hMh, e, l ds ek/; e l s Hkj dj , uihih, dks , d eW; l ph tkjh djaA

¼M-½ mi ; Dr l kj.kh ds Lralk ¼5½ ea fofufnZV vf/kdre dher ds fy, fofufnZV vuq fpr fofufeŕ; ka ds fofufnZV fofHkuu rjhds vkş iæyrk l s fHkuu vxj ekStnk fuekŕkvka }kjk , d ubl vksk/k dks ykş djrk gS rks ml s igys vksk/k ¼eW; fu; æ.k.½ vknş k] 2013 ds işkxkQ 2¼½ ds vuq kj vksk/k ¼eW; fu; æ.k.½ vknş k] 2013 ds rgr l ph II ea fofufnZV QkeZ I ds ek/; e l s , uihih, ea eW; fu/kkŕ.k gŕq vkonu djuk gkskA

¼p½ mi ; Dr vuq fpr fofufeŕ; ka dh mRiknu@vk; kr vkş fcØh ds l Ecu/k ea fuekŕkvka dks vksk/k ¼eW; fu; æ.k.½ vknş k] 2013 ds l ph II ds QkæZ III dks vkbŕ hMh, e, l ds ek/; e l s Hkj dj , uihih, dks gj frekgh dh fjkvZ l Lŕr djaA mi ; Dr vuq fpr fofufeŕ; ka ds fuekŕk dks dkbZ fuekŕk mRiknu cln djus dk bPNd gS rks bl dh l upuk , uihih, dks voxr dj; skA bl ds l Ecu/k ea vxj vuq fpr fofufeŕ; ka ds mRiknu vkş vk; kr dks cln djus dk bPNd gS rks cln djus dh frfFk l s N% eghus igys l ph II ds QkæZ IV ea Hkj dj , uihih, dks l Lŕr djaA

¼N½ fofuekŕk ; k foi.ku dEiuh] mijDr dffkr l kj.kh ea n'kkZ s vf/kdre eW; vkş 'krkædk ikyu ugha djrh gS rks os vko' ; d oLŕq; vf/kfu; e] 1955 ds l kFk i fBr Mhihl hvkş 2013 ds i ko/kkuka ds v/khu C; kt l fgr vf/ki Hkŕj jk'k dks tek djus ds fy, nk; h gksA

¼t½ bl vknş k ea mijDr l kj.kh ds Lralk ¼2½ ea dh rRLFkkuh i fof"V ea fofufnZV , s h fofufeŕ; ka ds i Ska dh vf/kdre dher fu; r gkus ds i j.kke Lo#i] vf/kdre vkş [knjk eW; fu/kkŕj vknş k ; fn dkbZ gkş tks fd bl vknş k l s i wZ tkjh gq gS Lor% gh vf/kØe.k gks tk; skA

[dka l a@170@38/2016@fo@Qk- l a 8¼38½@2016@Mhi h@, uihih, -&fMoh—II]

cythr fl g] l gk; d funşkd

**MINISTRY OF CHEMICALS AND FERTILIZERS****(Department of Pharmaceuticals)****(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)****ORDER**

New Delhi, the 10th November, 2016

**S.O. 3430(E).**—In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S.O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

**TABLE**

Sl. No.	Name of the Scheduled Formulation	Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Pralidoxime Chloride (2-PAM) Injection	Pralidoxime Chloride	1 ml 25 mg/ml	3.45
2.	Efavirenz Tablet	Efavirenz-200 mg	1 Tablet	20.17
3.	Imatinib Capsule	Imatinib-400 mg	1 Capsule	236.99
4.	Folic Acid Capsule	Folic Acid-5 mg	1 Capsule	5.23
5.	Benzoyl Peroxide Cream	Benzoyl Peroxide-2.50%	1 gm	2.18
6.	Clomiphene Capsule	Clomiphene-100 mg	1 Capsule	51.64
7.	Acetazolamide Capsule	Acetazolamide-250 mg	1 Capsule	4.03
8.	Salbutamol Capsule	Salbutamol-4 mg	1 Capsule	0.56
9.	Paracetamol Oral Liquid	Paracetamol 120mg/5ml	1 ml	0.49

**Note :**

- All the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS.
- Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

dál a	vuð ífr fofufefr dk uke	ízyrk	bðkb/	vf/kdre dher ¼#-½
1	2	3	4	5
1.	Qfujkekbú bltð'ku	Qfujkekbú - 22.75 fexk./fey	1 fey	1.03
2.	uSykðl klu bltð'ku	ukyðl klu & 0.4 fexk./fey	1 fey	80.49
3.	ykljksi ke bltð'ku	ykljksi ke & 2 fexk./fey	1 fey	7.22
4.	QuhVks u bltð'ku	QuhVks u & 25 fexk./fey	1 fey	2.33
5.	I § VktkbMhe bltð'ku ds fy, i kmMj	I § VktkbMhe & 250 fexk-	ifr ið	60.39
6.	I § VktkbMhe bltð'ku ds fy, i kmMj	I § VktkbMhe & 1 xke	ifr ið	194.19
7.	vkjVð ukVs \$ ¼ yQkMkðl hu&i kefkkekbú½ xksh	vkjVð ukVs & 50 fexk- +¼ yQkMkðl hu+i kefkkekbú 500 fexk- + 25 fexk-)	dkEch ið	19.69
8.	eS/kðyksi kekbM vkjy fyð; bM	eS/kðyksi kekbM 5 fexk./fey	1 fey	0.41
9.	LV§Vkdhud bltð'ku	LV§Vkdhud &7,50,000 vkbž; w	ifr ið	1,168.12
10.	LV§Vkdhud bltð'ku	LV§Vkdhud &15,00,000 vkbž; w	ifr ið	1,660.84
11.	i kohMu vk; kMhu 1 kš; w ku	i kohMu vk; kMhu 5%	1 fey	0.33
12.	cS/kefkl klu dhe	cS/kefkl klu & 0.05%	1 xke	0.54

13.	Vksi hdkkebM vkbZ Mksi	Vjksi hdkkebM & 1%	1 fefy	9.34
14.	I S/jhekbM I kS; w ku	I S/jhekbM & 20% %du'kuVVM Mk; W; w ku½ ds fy,	1 fefy	0.29
15.	eShVkiW bltD'ku	eShVkiW & 20%	1 fefy	0.27
16.	jShVhMhu bltD'ku	jShVhMhu & 25 fexk-/fefy	1 fefy	1.48
17.	MkbZ kDykekbZ bltD'ku	MhI DykekbZ & 10 fexk-/fefy	1 fefy	2.44
18.	I hi kDykbI kl hu vkbVedV	I hi kDykbI kl hu & 0.3%	1 xke	1.04
19.	tuVkekbZ hu Mksi	tuVkekbZ hu & 0.3%	1 fefy	0.84
20.	Ihykdkji hu Mksi	i hykdkji hu & 2%	1 fefy	9.38
21.	Vheksyky Mksi	Vheksyky & 0.25%	1 fefy	4.79
22.	, Vksi hu Mksi	, Vksi hu & 1%	1 fefy	3.05
23.	gkekVkiW hu Mksi	gkekVkiW hu & 2%	1 fefy	5.53
24.	fcVkeFkkl klu bltD'ku	fcVkeFkkl klu & 4 fexk-/fefy	1 fefy	3.89
25.	gkbMkVkiW ku bltD'ku	gkbMkVkiW ku & 200 fexk-	i fr i d	53.39
26.	jhQkeihl hu xksh	jhQkeihl hu & 300 fexk-	1 xksh	2.72
27.	flydkuktksy dS l y	flydkuktksy & 100 fexk-	1 dS l y	23.44
28.	flydkuktksy dS l y	flydkuktksy & 200 fexk-	1 dS l y	33.87
29.	bQkohjut dS l y	bQkohjut & 200 fexk-	1 dS l y	21.43
30.	bQkohjut dS l y	bQkohjut & 600 fexk-	1 dS l y	55.81
31.	jhVkiWkohj dS l y	jhVkiWkohj & 100 fexk-	1 dS l y	26.18
32.	i gkfl Vkeky I iktVjh	i gkfl Vkeky & 80 fexk-	1 I iktVh	6.04
33.	i gkfl Vkeky I iktVjh	i gkfl Vkeky & 170 fexk-	1 I iktVh	7.14
34.	i gkfl Vkeky vkWj fyD; bM	i gkfl Vkeky & 125 fexk-/5 fefy	1 fefy	0.31

ukW/ %

%d½ I jdkj }kjk bl i xdkj fu; r dh xbz vkj vf/kl fpr dh xbz vf/kdre dher %ku LFkkuh; dj] tks ykxw gk½ I s vf/kd dher ij vuq fpr fofufeR; ka ds ckMM ; k tufjd ; k nksuka : i karjka dks cp jgs vuq fpr fofufeR; ka ds I Hkh fofuekRk] mi ; Pr I kj.kh ds Lralk (5) ea of.kR vf/kdre dher %ku LFkkuh; dj] tks ykxw gk½ I s vf/kd I Hkh , s h fofufeR; ka dh dher dk v/kkeq[kh i pjjh{k.k djaxA

%[k½ I Hkh ekStnk fuekRkvka dks mi ; Pr dffkr vuq fpr fofufeR; ka ds vf/kdre [kqjk dher mi ; Pr I kj.kh ds Lralk %½ ea fofufnZV vf/kdre dher LFkkuh; dj I fgr I s de gS rkj tgka dgh Hkh ykxw gk½ vkSk/k %eW; fu; a=k.k½ vkns k] 2013 ds i gkxkQ 13(2) ds vuq kj ml dks ekStnk vf/kdre [kqjk dher dks cuk, j[kuk gkxkA

%½ vxj fuekRkvka us mi ; Pr I kj.kh ds Lralk (5) ea of.kR vf/kdre dher ij I jdkj dks okLro ea Hkqrku fd; k gS ; k ; g ns gS rks os LFkkuh; djka dks tkM+I dS gA

%k½ vkSk/k %eW; fu; a=k.k½ vkns k] 2013 ds i gkxkQ 11 ea fn, x, i ko/kkuka ds rgr I EcfU/kr fuekRkvka dks mi ; Pr I kj.kh ds Lralk %½ ea fofufnZV vf/kdre dher ds vk/kkj ij vuq fpr fofufeR; ka ds i dka ds fy,

vf/kdre dher fu/klfjr djA fuekark vksk/k veW; fu; a-k.k% vkn'sk] 2013 ds i'gkxkQ 24 ds rgr QkeZ V ea vf/kl ipuk dh rkjh[k l s vkbh hMh, e, l ds ek/; e l s Hkj dj , uihih, dks , d eW; l ph tkjh djA

¼M-½ mi; Dr l kj.kh ds Lrñk ¼5½ ea fofufnZV vf/kdre dher ds fy, fofufnZV vuq fpr fofufeR; ka ds fofufnZV fofHkuu rjhds vkj icyrk l s fHkuu vxj ekStnk fuekarkvka }kj k , d ubZ vkskf/k dks ykp djrk gS rks ml s igys vksk/k veW; fu; a-k.k% vkn'sk] 2013 ds i'gkxkQ 2¼½ ds vuq kj vksk/k veW; fu; a-k.k% vkn'sk] 2013 ds rgr l ph II ea fofufnZV QkeZ I ds ek/; e l s , uihih, ea eW; fu/klj .k grq vkonu djuk gksxA

¼p½ mi; Dr vuq fpr fofufeR; ka dh mRiknu@vk; kr vkj fcØh ds l Ecl/k ea fuekarkvka dks vksk/k veW; fu; a-k.k% vkn'sk] 2013 ds l ph II ds QkeZ III dks vkbh hMh, e, l ds ek/; e l s Hkj dj , uihih, dks gj frekgh dh fjkvZ iLrR djxkA mi; Dr vuq fpr fofufeR; ka ds fuekark dks dkbZ fuekark mRiknu cln djus dk bPNd gS rks bl dh l ipuk , uihih, dks voxr dj; xkA bl ds l Ecl/k ea vxj vuq fpr fofufeR; ka ds mRiknu vkj vk; kr dks cln djus dk bPNd gS rks cln djus dh frfFk l s N% eghus igys l ph II ds QkeZ IV ea Hkj dj , uihih, dks iLrR djxkA

¼N½ fofuekark ; k foi .ku dEiuh] mijDr dffkr l kj.kh ea n'kkZ s vf/kdre eW; vkj 'krkxdk ikyu ugha djrh gS rks os vko'; d oLrq; vf/kfu; e] 1955 ds l kFk i fBr Mhihl hvkj 2013 ds i ko/kkuka ds v/khu C; kT l fgr vf/kl Hkfjr jk'k dks tek djus ds fy, nk; h gksxA

¼t½ bl vkn'sk ea mijDr l kj.kh ds Lrñk ¼2½ ea dh rRLFkuh i fof"V ea fofufnZV , d h fofufeR; ka ds i Sdk dh vf/kdre dher fu; r gkus ds i f. ke Lo#i] vf/kdre vkj [kqj k eW; fu/klfjr vkn'sk ; fn dkbZ gkj tks fd bl vkn'sk l s i mZ tkjh gq gS Lor% gh vf/kØe.k gks tk; xkA

[dkal a@170@38/2016@fo@Qk- l 8¼38½@2016@Mhih@, uihih, -&fMoh—II]

cythr fl g] l gk; d funskd

### ORDER

New Delhi, the 10th November, 2016

**S.O. 3431(E).**—In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 644(E), dated 2nd March, 2016, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

**TABLE**

Sl. No.	Name of the Scheduled Formulation	Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Pheniramine Injection	Pheniramine-22.75mg/ml	1 ml	1.03
2.	Naloxone Injection	Naloxone-0.4 mg/ml	1 ml	80.49
3.	Lorazepam Injection	Lorazepam-2mg/ml	1 ml	7.22
4.	Phenytoin Injection	Phenytoin-25 mg/ml	1 ml	2.33
5.	Ceftazidime Powder for Injection	Ceftazidime-250 mg	Each pack	60.39
6.	Ceftazidime Powder for Injection	Ceftazidime-1 gm	Each pack	194.19
7.	Artesunate + (Sulphadoxine+ Pyrimethamine) Tablet	Artesunate-50mg + (Sulphadoxine + Pyrimethamine 500mg+25 mg)	Combi Pack	19.69
8.	Metoclopramide Oral Liquid	Metoclopramide 5mg/ml	1 ml	0.41
9.	Streptokinase Injection	Streptokinase 7,50,000 IU	Each Pack	1168.12
10.	Streptokinase Injection	Streptokinase 15,00,000 IU	Each Pack	1660.84
11.	Povidone Iodine Solution	Povidone Iodine-5%	1 ml	0.33

12.	Betamethasone Cream	Betamethasone 0.05%	1 gm	0.54
13.	Tropicamide Eye Drop	Tropicamide 1%	1 ml	9.34
14.	Cetrimide Solution	Cetrimide 20% (concentrate for dilution)	1 ml	0.29
15.	Mannitol Injection	Mannitol 20%	1 ml	0.27
16.	Ranitidine Injection	Ranitidine-25 mg/ml	1 ml	1.48
17.	Dicyclomine Injection	Dicyclomine-10 mg/ml	1 ml	2.44
18.	Ciprofloxacin Ointment	Ciprofloxacin-0.3%	1 gm	1.04
19.	Gentamicin Drops	Gentamicin-0.3%	1 ml	0.84
20.	Pilocarpine Drops	Pilocarpine-2%	1 ml	9.38
21.	Timolol Drops	Timolol-0.25%	1 ml	4.79
22.	Atropine Drops	Atropine-1%	1 ml	3.05
23.	Homatropine Drops	Homatropine-2%	1 ml	5.53
24.	Betamethasone Injection	Betamethasone-4 mg/ml	1 ml	3.89
25.	Hydrocortisone Injection	Hydrocortisone-200 mg	Each Pack	53.39
26.	Rifampicin Tablet	Rifampicin-300 mg	1 Tablet	2.72
27.	Fluconazole Capsule	Fluconazole-100 mg	1 Capsule	23.44
28.	Fluconazole Capsule	Fluconazole-200 mg	1 Capsule	33.87
29.	Efavirenz Capsule	Efavirenz-200 mg	1 Capsule	21.43
30.	Efavirenz Capsule	Efavirenz-600 mg	1 Capsule	55.81
31.	Ritonavir Capsule	Ritonavir-100 mg	1 Capsule	26.18
32.	Paracetamol Suppository	Paracetamol 80mg	1 Suppository	6.04
33.	Paracetamol Suppository	Paracetamol 170mg	1 Suppository	7.14
34.	Paracetamol Oral Liquid	Paracetamol 125mg/5ml	1 ml	0.31

**Note :**

- All the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS.
- Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

[PN/170/38/2016/F/F. No. 8(38)/2016/D.P./NPPA-Div.-II]

BALJIT SINGH, Asstt. Director

## vkn'sk

ubl fnYyh] 10 uoEcj] 2016

dk-vk- 3432¼½&jk"Vh; vksk/k eW; fu/kk].k ikf/kdj.k Hkkjr ljdkj ds jlk; u vkj mojd ea=kky; }kjk tkjhdk0 vk0 1394¼½ rkjh[k 30 eb] 2013 vkj dk0 vk0 701¼½ rkjh[k 10 ekb] 2016 ds l kFk i fBr vksk/k ¼dher fu; æ.k.½ vkn'sk] 2013 ds i jk 4, 10, 11, 14, 16, 17 vkj 18 }kjk inRr 'kFDr; ka dk iz;ksx djrs gq] rFkk Hkkjr ljdkj ds jlk; u vkj mojd ea=kky;] jk"Vh; vksk/k eW; fu/kk].k ikf/kdj.k ds vkn'sk dk- vk- 1561¼½ fnukad 27 viSy] 2016 dh l kj.kh ea mYyf[kr Øe la 28 vkj 29 dæ'k% dks tgk; rd ml dk l Ecu/k uhps dh l kj.kh ds fofufeR i d l s g] mu ckrka ds fl ok; vf/kØkUr djrs gq ftlUga, s s vf/kØe.k ds i wZ fd; k x; k gS ; k djus dk yki fd; k x; k g] uhps dh l kj.kh ds Lralk ½½ ea fofufnZV vf/kdre dher dks mDr l kj.kh ds Lralk ¾¾ vkj ¼¾ ea dh Øe'k% rRLFkkuh i fof"V; ka ea fofufnZV i cyrk vkj bdkbZ ¼; fuV½ l fgr ml l kj.kh ds Lralk ½½ ea dh rRLFkkuh i fof"V ea fofufnZV vuq fpr fofufeR; ka ea l s i R; d dh] LFkkuh; dj] ; fn dkbZ g] dks NkMdj vf/kdre dher ds #i ea fu; r djrh gA

l kj.kh

dZl a	vuq fpr fofufeR dk uke	icyrk	bdkbZ	vf/kdre dher ¼#-½
1	2	3	4	5
1-	dkckDI heFkhl \$yYkll	dkckDI heFkhl \$yYkll 0-5%	1 fefy	11-85
2-	dkckDI heFkhl \$yYkll	dkckDI heFkhl \$yYkll 1-00%	1 fefy	16-44

ukW %

¼d½ ljdkj }kjk bl izdkj fu; r dh xbl vkj vf/kI fpr dh xbl vf/kdre dher ¼ku LFkkuh; dj] tks ykxw gk½ l s vf/kd dher ij vuq fpr fofufeR; ka ds ckmM ; k tufjd ; k nksuka : i karjka dks cp jgs vuq fpr fofufeR; ka ds l Hkh fofuekRk] mi ; Ør l kj.kh ds Lralk (5) ea of.kR vf/kdre dher ¼ku LFkkuh; dj] tks ykxw gk½ l s vf/kd l Hkh, s h fofufeR; ka dh dher dk v/kkq[kh i qjh{k.k djæA

¼k½ l Hkh ekStnk fuekRkvka dks mi ; Ør dffkr vuq fpr fofufeR; ka ds vf/kdre [kqjk dher mi ; Ør l kj.kh ds Lralk ½½ ea fofufnZV vf/kdre dher LFkkuh; dj l fgr l s de gS rkj tgka dgh Hkh ykxw gk½ vksk/k ¼eW; fu; æ.k.½ vkn'sk] 2013 ds i jkxkQ 13(2) ds vuq kj ml dks ekStnk vf/kdre [kqjk dher dks cuk, j[kuk gkxkA

¼x½ vxj fuekRkvka us mi ; Ør l kj.kh ds Lralk (5) ea of.kR vf/kdre dher ij ljdkj dks okLro ea Hkqrku fd; k gS ; k ; g ns gS rks os LFkkuh; djka dks tkM+ l drs gA

¼k½ vksk/k ¼eW; fu; æ.k.½ vkn'sk] 2013 ds i jkxkQ 11 ea fn, x, i ko/kkuka ds rgr l Ecu/k fuekRkvka dks mi ; Ør l kj.kh ds Lralk ½½ ea fofufnZV vf/kdre dher ds vk/kkj ij vuq fpr fofufeR; ka ds l dka ds fy, vf/kdre dher fu/kk]r djæ fuekRk vksk/k ¼eW; fu; æ.k.½ vkn'sk] 2013 ds i jkxkQ 24 ds rgr QkMZ V ea vf/kI upuk dh rkjh[k l s vkbZ hMh, e, l ds ek/; e l s Hkj dj, ui hi h, dks, d eW; l ph tkjh djæA

¼M-½ mi ; Ør l kj.kh ds Lralk ½½ ea fofufnZV vf/kdre dher ds fy, fofufnZV vuq fpr fofufeR; ka ds fofufnZV fofHku rjhds vkj i cyrk l s fHku vxj ekStnk fuekRkvka }kjk, d ubZ vksk/k dks yk djrk gS rks ml s i gys vksk/k ¼eW; fu; æ.k.½ vkn'sk] 2013 ds i jkxkQ 2¼½ ds vuq kj vksk/k ¼eW; fu; æ.k.½ vkn'sk] 2013 ds rgr l ph II ea fofufnZV QkZ I ds ek/; e l s, ui hi h, ea eW; fu/kk].k graq vkonsu djuk gkxkA

¼p½ mi ; Ør vuq fpr fofufeR; ka dh mRi knu@vk; kr vkj fcØh ds l Ecu/k ea fuekRkvka dks vksk/k ¼eW; fu; æ.k.½ vkn'sk] 2013 ds l ph II ds QkMZ III dks vkbZ hMh, e, l ds ek/; e l s Hkj dj, ui hi h, dks gj frekgh dh fji kZ l Zrq djskA i ; Ør vuq fpr fofufeR; ka ds fuekZk dks dkbZ fuekRk mRi knu cln djus dk bPNd gks rks bl dh l upuk, ui hi h, dks voxr dj; skA bl ds l Ecu/k ea vxj vuq fpr fofufeR; ka ds mRi knu vkj vk; kr dks cln djus dk bPNd gS rks cln djus dh frffk l s N% eghus i gys l ph II ds QkMZ IV ea Hkj dj, ui hi h, dks i Zrq djskA

¼N½ fofuekRk ; k foi.ku dEi uh] mi jkØr dffkr l kj.kh ea n'kZ s vf/kdre eW; vkj 'krkæ dk i kyu ugha djrh gS rks os vko'; d oLrq; vf/kfu; e] 1955 ds l kFk i fBr Mhi hl hvk] 2013 ds i ko/kkuka ds v/khu C; kt l fgr vf/ki HkkfjR jk'k dks tek djus ds fy, nk; h gkæA



1/4th bl vkn'sk ea mijkDr l kj.kh ds Lralk 1/2% ea dh rRLfkkuh i fof"V ea fofufn"V , s h fofufeir; ka ds i Sdk dh vf/kdre dher fu; r gkus ds ifj.kke Lo#i] vf/kdre vkj [knjk eW; fu/kkZjr vkn'sk ; fn dkbZ gkj tks fd bl vkn'sk l siwZ tkjh gq g\$ Lor% gh vf/kØe.k gks tk; xA

[dkal a@170@38/2016@fo@Qk- I 8%38%@2016@Mhi h@, ui hi h, -&fMoh—II]

cythr fl g] l gk; d fun'skd

## ORDER

New Delhi, the 10th November, 2016

**S.O. 3432(E).**—In exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1561(E), dated 27th April, 2016 regarding formulation packs mentioned in the table at Sl. Nos. 28 & 29 respectively, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

**TABLE**

Sl. No.	Name of the Scheduled Formulation	Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Carboxymethylcellulose Drops	Carboxymethylcellulose-0.5%	1 ml	11.85
2.	Carboxymethylcellulose Drops	Carboxymethylcellulose-1%	1 ml	16.44

### Note :

- All the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS.
- Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

- (h) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

[PN/170/38/2016/F.F. No. 8(38)/2016/D.P./NPPA-Div.-II]

BALJIT SINGH, Assistant Director

### vknsk

ubz fnYyh] 10 uoEcj] 2016

dk-vk- 3433½&jk"Vh; vkSk/k eW; fu/kk].k i kf/kdj.k Hkkjr ljdkj ds jlk; u vkj mojd ea=kky; }kjk tkjh dk0 vk0 1394½ rkjh[k 30 eb] 2013 vkj dk0 vk0 701½ rkjh[k 10 ekp] 2016 ds l kFk i fBr vkSk/k dhher fu; a=k.k½ vknsk] 2013 ds ijk 5, 11 vkj 15 }kjk inRr 'kfDr; ka dk iz ks djrs gq] rFkk Hkkjr ljdkj ds jlk; u vkj mojd ea=kky; }jk"Vh; vkSk/k eW; fu/kk].k i kf/kdj.k fti dks l f{kr : i ea , uihih, dgk tkrk gq uhrs dh l kj.kh ds Lrkk ½½ ea fofufnZV [knjk eW; dks mDr l kj.kh ds Lrkk ¼¾ ¼¾ vkj ½½ ea dh Øe'k% rRLFkkuh i fof"V; ka ea fofufnZV izcyrk bdkbz ¼; fuV½ vkj fufel vkj foi.ku dEifu; ka l fgr Øe'k% Lrkk ½½ ea dh rRLFkkuh i fof"V ea l s iR; d dh] LFkkuh; dj] ; fn dkbz gq dks NkM-dj vf/kdre [knjk eW; ds #i ea fu; r djrh gA

l kj.kh

dZl a	vuq fpr fofufelr dk uke@ckM dk uke	izcyrk	bdkbz	fufel vkj foi.ku }kjk dæ'k%	[knjk eW; ¼#-½
1	2	3	4		5
1.	VufyxfyifVu\$ eVQkfeU , pl h, y xkyh Wufyed , e 1000%	iR; d vfyf r ck; ys j xkyh e% VufyxfyifVu gkbMkckekbM gkbM\$ VufyxfyifVu-20 fexk- ds cjkj eVQkfeU , pl h, y-1000 fexk- ¼, DI VMM fjyht e%	1 xkyh	e l l XyuekdZ QkekL; fVdYI fyfeVM vkj e l l eDykMI QkekL; fVdYI fyfeVM	11.65
2.	VufyxfyifVu\$ eVQkfeU , pl h, y xkyh WutfyDI , e 1000%	iR; d vfyf r ck; ys j xkyh e% VufyxfyifVu gkbMkckekbM gkbM\$ VufyxfyifVu-20 fexk- ds cjkj eVQkfeU , pl h, y-1000 fexk- ¼, DI VMM fjyht e%	1 xkyh	e l l XyuekdZ QkekL; fVdYI fyfeVM vkj e l l VkuV QkekL; fVdYI fyfeVM	11.65
3.	VufyxfyifVu\$ eVQkfeU , pl h, y xkyh Wufxy; u , e 1000%	iR; d vfyf r ck; ys MZ xkyh e% VufyxfyifVu gkbMkckekbM gkbM\$ VufyxfyifVu-20 fexk- ds cjkj eVQkfeU , pl h, y-1000 fexk- ¼ l VMM fjyht QkekL; e%	1 xkyh	e l l d fMyk gVfKds j fyfeVM	11.65
4.	VufyxfyifVu\$ eVQkfeU , pl h, y xkyh ¼, l vkj ½	iR; d vfyf r ck; ys j xkyh e% VufyxfyifVu gkbMkckekbM gkbM\$ VufyxfyifVu-20 fexk- ds cjkj eVQkfeU , pl h, y-1000 fexk- ¼ l VMM fjyht QkekL; e%	1 xkyh	e l l yfi u fyfeVM	11.65

5.	VufyxfyifVu\$ eVQkfeU , pl h, y xksh WutfyDI , e 500%	iR; d vfyfir ck; ys j xksh e% VufyxfyifVu gkbMkckebM gkbM\$ VufyxfyifVu-20 fexk- ds cjkj eVQkfeU , pl h, y-500 fexk- %, DI VMM fjyht e%	1 xksh	eI l l XyuekdZ QkekL; fVdYI fyfeVM vkj eI l l VkuV QkekL; fVdYI fyfeVM	11.14
6.	VufyxfyifVu\$ eVQkfeU xksh , pl h, y Wufyed , e 500%	iR; d vfyfir ck; ys j xksh e% VufyxfyifVu gkbMkckebM gkbM\$ VufyxfyifVu-20 fexk- ds cjkj eVQkfeU , pl h, y-500 fexk- %, DI VMM fjyht e%	1 xksh	eI l l XyuekdZ QkekL; fVdYI fyfeVM vkj eI l l eDykmI QkekL; fVdYI fyfeVM	11.14
7.	VufyxfyifVu\$ eVQkfeU , pl h, y xksh Wbvkj %	iR; d vfyfir ck; ys j xksh e% VufyxfyifVu gkbMkckebM gkbM\$ VufyxfyifVu-20 fexk- ds cjkj eVQkfeU , pl h, y -500 fexk- %, DI VMM fjyht e%	1 xksh	eI l l XyuekdZ QkekL; fVdYI fyfeVM vkj eI l l , fke ck; kQkekZ fyfeVM	11.14
8.	fMDykQul I kfm; e\$ i j kfi Vkeky xksh	iR; d vfyfir xksh e% fMDykQul I kfm; e 50 fexk- % xj Vkejfi M\$ i j % i j kfi Vkeky 325 fexk-	1 xksh	eI l l foMykl ck; kVd fyfeVM vkj	2.30
9.	vkj & gbj Fkks kV/u bltD'ku %tkbj ki 40000%	iR; d y; kQtkbM ok; y e% vkj & gbj Fkks kV/u %vkj & gbj k% 40000 vkbZ %	ifr i d	eI l l d fMyk gVfKds j fyfeVM	8938.96
10.	vkj & gbj Fkks kV/u bltD'ku %tkbj ki 20000%	iR; d y; kQtkbM ok; y e% vkj & gbj Fkks kV/u %vkj & gbj k% 20000 vkbZ %	ifr i d	eI l l d fMyk gVfKds j fyfeVM	4925.59
11.	eVQkfeU , pl h, y , I vkj \$ okSyhckll xksh	iR; d vfyfir ck; ys MZ xksh e% eVQkfeU , pl h, y 500 fexk- % I VMM fjyht QkbeZ e% okSyhckll 0-3 fexk-	10 xksh	eI l l l kbukde QkekL; fVdYI fyfeVM vkj eI l l vtrk QkekZ fyfeVM	57.62

uk\$ %

1/2% fofuekrk mi ; Dr nh xbl fofufn"V QkbeZ ku tks pubZ Mx\$ Mhi hl hvkj 2013 ds i j kxkQ 24% ds rgr mi ; Dr nh xbl I kj.kh ds Lrllk 1/2% es fofufnZV [knjk eW; fu/kkZjr dja

1/2% vxj fuekrkvka us mi ; Dr I kj.kh ds Lrllk (6) ea of.kr vf/kdre dher ij I jdkj dks okLro ea Hkxrk fd; k g\$ ; k ; g ns g\$ rks os LFkkuh; dja dks tkM+ I drs g\$

1/2% vksk/k %W; fu; a.k.k% vksk/k] 2013 ds i j kxkQ 11 ea fn, x, i ko/kkuka ds rgr fuekrkvka dks mi ; Dr I kj.kh ds Lrllk 1/2% ea fofufnZV [knjk eW; ds vk/kkj ij vud fpr fofufeir; ka ds i dka ds fy, [knjk eW; fu/kkZjr dja fuekrkvka us mi ; fu; a.k.k% vksk/k] 2013 ds i j kxkQ 24 ds rgr QkbeZ V ea vf/kl ipuk dh rkjh[k I s , d eW; I ph , ui hi h, dks vkbZ hMh, e, I ds ek/; e I s tkjh dja

¼k½ mi ; Ðr xş vf/kdr dher ¼[knj k eW; ½ dny mi ; Ðr fuekZrk@foi.ku ds fy, ykxw gS tŞ k fd mlgkaus vksk/k eW; fu; æ.k.½ vks'k] 2013 ds rgr vuq) eW; fu/kkZ.k@l d kks'ku ds fy, QkMZ I ij tek fd; k x; k Fkk vkş l jdkj }kjk fu/kkZjr l Hkh ykxw oşkkfud vko'; drkvk dh i frZ ds v/khu i kl fxd fof/k; k@fu; eka ds vLrxr tŞ fd dñh; @jkT; ykbl fl æ vkWfKfjVh ds l {ke i kf/kdkjh }kjk eW; QDpfjæ ykbl d eatjh ds rgr l æf/kr fofufeR fuekZrk@foi.ku dEi fu; ka tks vuqkyu djrh gA

¼M-½ mi ; Ðr fofufeR; ka dh mRiknu@vk; kr vkş fcØh ds l ECU/k ea l EcfU/kr fuekZrkvk dks vksk/k eW; fu; æ.k.½ vks'k] 2013 ds l ph II ds QkMZ III dks vkbZ hMh, e, l ds ek/; e l s Hkj dj , ui hi h, dks gj frekgh dh fjikVZ i LrR djxkA mi ; Ðr fofufeR; ka ds fuekZk dks dkbZ fuekZrk mRiknu cUn djus dk bPNd gks rks bl dh l puk , ui hi h, dks voxr dj; xkA bl ds l ECU/k ea vxj fofufeR; ka ds mRiknu vkş vk; kr dks cUn djus dk bPNd gS rks cUn djus dh frfFk l s N% eghus igys l ph II ds QkMZ IV ea Hkj dj , ui hi h, dks i LrR djxkA

¼p½ fofuekZrk ; k foi.ku dEi uh] mijkDr fofufeR; ka vkş fofufnZV 'krkæ dk ikyu ugha djrh gA rks os vko'; d oLrqj vf/kfu; e] 1955 ds l kFk i fBr Mhi hl hvkş 2013 ds i ko/kkuk ds v/khu C; kt l fgr vf/ki Hkkfjr jkf'k dks tek djus ds fy, nk; h gkxkA

¼N½ bl vks'k ea mijkDr l kj.kh ds Lrkk ¼2½ ea dh rRLFkkuh i fof"V ea fofufnZV fofufeR; ka ds i skA dh [knj k eW; fu; r gkus ds ifj.kke Lo#i] vks'k tks fd bl vks'k l s i wZ tkjh gq gş Lor% gh fujLr gks tk; xA

[dkal a@170@38/2016@fo@Qk- l d 8¼38¼@2016@Mhi h@, ui hi h, -&fMoh—II]

cythr fl g] l gk; d funs'kd

## ORDER

New Delhi, the 10th November, 2016

**S.O. 3433(E).**—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

**TABLE**

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company respectively	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Teneligliptin + Metformin HCl Tablet (Tenlimac M 1000)	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 1000mg (as extended release)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Macleods Pharmaceuticals Ltd.	11.65
2.	Teneligliptin + Metformin HCl Tablet (Tenzulix M 1000)	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 1000mg (as extended release)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd.	11.65

3.	Teneligliptin + Metformin HCl Tablet (Tenglyn M 1000)	Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 1000mg (as sustained release form)	1 Tablet	M/s Cadila Healthcare Ltd.	11.65
4.	Teneligliptin + Metformin HCl (SR)Tablet	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 1000mg (as sustained release form)	1 Tablet	M/s Lupin Limited	11.65
5.	Teneligliptin + Metformin HCl Tablet (Tenzulix M 500)	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 500mg (as extended release)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd.	11.14
6.	Teneligliptin + Metformin HCl Tablet (Tenlimac M 500)	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 500mg (as extended release)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Macleods Pharmaceuticals Ltd.	11.14
7.	Teneligliptin + Metformin HCl (ER)Tablet	Each uncoated bilayer tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin HCl 500mg (as extended release)	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Anthem BioPharma Pvt. Ltd.	11.14
8.	Diclofenac Sodium + Paracetamol Tablet	Each uncoated tablet contains: Diclofenac Sodium 50mg (Gastro-Resistant Pellets) Paracetamol 325mg	1 Tablet	M/s Windlas Biotech Ltd.	2.30
9.	r-HuErythropoietin Injection (Zyrop 40000)	Each Lyophilized vial contains: r-HuErythropoietin (r-HuEPO) 40000 IU	Each Pack	M/s Cadila Healthcare Ltd.	8938.96
10.	r-HuErythropoietin Injection (Zyrop 20000)	Each Lyophilized vial contains: r-HuErythropoietin (r-HuEPO) 20000 IU	Each Pack	M/s Cadila Healthcare Ltd.	4925.59
11.	Voglibose + Metformin HCl (SR) tablet	Each uncoated bilayered tablet contains: Metformin HCl (in sustained release form) – 500mg Voglibose 0.3mg	10 Tablets	M/s Synokem Pharmaceuticals Ltd. / M/s Ajanta Pharma Ltd.	57.62

**Note:**

- (a) The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS.
- (d) The above mentioned retail price is applicable only to the individual manufacturers / marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
- (e) The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand(s) superseded.

[PN/170/38/2016/F/ F. No. 8(38)/2016/D.P./NPPA-Div.-II]

BALJIT SINGH, Assistant Director